Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis

Documenti analoghi

• Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
  di: Peiying Zuo, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
  di: Neha Thakre, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults
  di: Jaime Algorta, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
  di: Jincheng Yang, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
  di: Sumit Bhatnagar, et al.
  Pubblicazione: (2024)